PMID- 21428180
OWN - NLM
STAT- MEDLINE
DCOM- 20110426
LR  - 20151119
IS  - 1220-4749 (Print)
IS  - 1220-4749 (Linking)
VI  - 48
IP  - 2
DP  - 2010
TI  - Anti C1q antibodies in cutaneous lupus erythematosus.
PG  - 159-63
AB  - Autoantibodies against C1q are strongly linked to immune-complex disorders like 
      systemic lupus erythematosus (SLE). Although anti-C1q antibodies have received 
      much interest in the recent years, their biological functions remain unclear. 
      Anti-C1q antibodies are strongly associated with lupus nephritis. Recent studies 
      describe apoptosis as a key player in LE pathogenesis and C1q is an important 
      opsonin, playing a central role in the uptake of apoptotic blebs. The aim of this 
      study was to evaluate serum anti C1q antibodies, C1q with circulating immune 
      complexes and correlation between serology and cutaneous apoptosis in patients 
      with cutaneous lupus erythematosus. MATERIAL AND METHODS: 79 subjects were 
      recruited and divided into 4 groups-13 healthy controls, 26 with discoid chronic 
      lupus (DLE), 23 with systemic lupus erythematosus (SLE) and 17 with subacute 
      lupus erythematosus (SCLE). Blood samples and skin punched-biopsy specimens were 
      performed. Serum anti-C1q antibodies and C1q associated to the immune complexes 
      concentrations were determined by ELISA. Cutaneous caspase-3 expression was 
      evaluated by immunohistochemistry. RESULTS: SLE and SCLE patients had 
      significantly higher levels of anti-C1q antibodies and serum C1q-CIC levels when 
      compared to healthy controls (p < 0.05). Serum anti-C1q antibodies correlated 
      with proteinuria in SLE patients (p < 0.05). Anti C1q antibodies levels also 
      correlated with cutaneous caspase 3 expression in SLE and SCLE patients (both p < 
      0.05). CONCLUSIONS: Anti C1q antibodies might play a pathogenic role in SCLE 
      pathogenesis and being positively associated with cutaneous apoptosis markers 
      might be associated with a negative prognosis and secondary SLE development.
FAU - Balanescu, Eugenia
AU  - Balanescu E
AD  - III Section Internal Medicine, "Colentina" Clinical Hospital, Bucharest, Romania. 
      plbalanescu@gmail.com
FAU - Tanasescu, C
AU  - Tanasescu C
FAU - Balanescu, P
AU  - Balanescu P
FAU - Olteanu, Rodica
AU  - Olteanu R
FAU - Badea, Camelia
AU  - Badea C
FAU - Petrutescu, Brandusa
AU  - Petrutescu B
FAU - Grancea, Camelia
AU  - Grancea C
FAU - Vagu, Codruta
AU  - Vagu C
FAU - Bleotu, Coralia
AU  - Bleotu C
FAU - Ruta, Simona
AU  - Ruta S
FAU - Ardeleanu, Carmen
AU  - Ardeleanu C
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Rom J Intern Med
JT  - Romanian journal of internal medicine = Revue roumaine de medecine interne
JID - 9304507
RN  - 0 (Autoantibodies)
RN  - 0 (Biomarkers)
RN  - 0 (Immunologic Factors)
RN  - 80295-33-6 (Complement C1q)
RN  - EC 3.4.22.- (Caspase 3)
SB  - IM
MH  - Adult
MH  - Autoantibodies/*immunology
MH  - Autoimmunity/immunology
MH  - Biomarkers
MH  - Caspase 3/immunology
MH  - Complement C1q/*immunology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Immunologic Factors/analysis
MH  - Lupus Erythematosus, Cutaneous/*immunology
MH  - Lupus Erythematosus, Discoid/*immunology
MH  - Lupus Erythematosus, Systemic/complications/*immunology
MH  - Lupus Nephritis/etiology/*immunology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
EDAT- 2010/01/01 00:00
MHDA- 2011/04/27 06:00
CRDT- 2011/03/25 06:00
PHST- 2011/03/25 06:00 [entrez]
PHST- 2010/01/01 00:00 [pubmed]
PHST- 2011/04/27 06:00 [medline]
PST - ppublish
SO  - Rom J Intern Med. 2010;48(2):159-63.